A family case report of parathyroid carcinoma associated with CDC73 mutation in hyperparathyroidism-jaw tumor syndrome

Yian Gu, Yuanyuan Ye, Hua Shu, Lina Chang, Yinghui Xie, Fengao Li, Tiehong Zhu, Ming Liu, Qing HeFrontiers in Endocrinology 2024 · DOI

Abstract

Genetic testing is strongly recommended in cases of early-onset PHPT, family history, jaw tumors, renal and uterine involvement, atypical parathyroid tumors, and PC. This testing provides valuable information for personalized management, and counseling is available for affected families.

Introduction

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, yet approximately 5–10% of cases are hereditary. Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome is one of the rarest and most clinically significant forms. It is characterized by a high risk (15–20%) of parathyroid carcinoma (PC), an aggressive malignancy, and variable manifestations such as ossifying fibromas of the jaw and renal lesions. This case report examines a family cluster of HPT-JT caused by a specific CDC73 gene mutation, emphasizing the role of genetic testing in navigating variable clinical presentations.

Methods

The study involved a comprehensive clinical and genetic workup of a 41-year-old male proband and his immediate family. Biochemical screening measured serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Advanced imaging, including parathyroid ultrasound, neck CT, and Parathyroid ECT (99mTc-MIBI), was used to localize tumors. Post-surgical histopathology and immunohistochemistry analyzed tumor tissue for Ki-67 expression and parafibromin loss. Finally, whole exome sequencing (WES) on peripheral blood samples identified germline mutations.

Results

A heterozygous frameshift mutation in CDC73 (NM_024529.4: c.687_688delAG (p.Arg229Serfs*37)) was identified, leading to a truncated, non-functional parafibromin protein. The proband exhibited severe biochemical abnormalities, with PTH levels reaching 1640.82 pg/mL (approximately 20 times the upper limit). Imaging studies successfully localized the hyperfunctioning lesion.

Imaging studies in the proband including parathyroid ultrasound (A), neck CT (B), and Parathyroid ECT (C).

Pathological analysis confirmed parathyroid carcinoma in the proband (Ki-67 index of 8%) and an atypical parathyroid tumor (APT) in his sister. Notably, while jaw tumors were absent, abdominal CT revealed bilateral renal cysts in the proband and a left renal cyst in the father, serving as critical diagnostic indicators for HPT-JT.

Discussion

This case illustrates the "incomplete penetrance" of HPT-JT syndrome, where family members with the same mutation show diverse symptoms. The absence of jaw tumors can lead to clinical mimicry of sporadic PHPT, but the high risk of malignancy necessitates a more aggressive surgical strategy, such as the extended ipsilateral thyroidectomy performed on the proband. The findings support the "two-hit" hypothesis, where germline CDC73 mutations predispose individuals to tumor growth upon a second somatic hit. Genetic sequencing is essential for early diagnosis and personalized management in families with early-onset PHPT or suspicious clinical features.

Summary updated

Abstract

Genetic testing is strongly recommended in cases of early-onset PHPT, family history, jaw tumors, renal and uterine involvement, atypical parathyroid tumors, and PC. This testing provides valuable information for personalized management, and counseling is available for affected families.
BibTeX
@inproceedings{gu2024family,
  author = {Yian Gu and Yuanyuan Ye and Hua Shu and Lina Chang and Yinghui Xie and Fengao Li and Tiehong Zhu and Ming Liu and Qing He},
  title = {{A family case report of parathyroid carcinoma associated with CDC73 mutation in hyperparathyroidism-jaw tumor syndrome}},
  booktitle = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1330185},
}
Figure